- PreveCeutical was recently featured in an interview by Proactive Investors
- The company is currently developing its Sol-gel drug delivery platform for delivery of cannabinoids
- Sol-gel technology is paving the way for direct nose-to-brain drug delivery
Innovative health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) was recently featured by Proactive Investors in a “Corporate News Update” regarding the company’s potentially game-changing Sol-gel drug delivery platform (http://cnw.fm/Xm1tL). The company earlier provided a written press release updating the Sol-gel program (http://cnw.fm/L2Lxb).
Sol-gel, a nickname for soluble gel, is taken through nasal (systemic) administration and quickly gels once it comes in contact with the mucosal tissue, paving the way for direct nose-to-brain delivery of drugs and effectively bypassing the stomach and intestines. This eliminates first-pass metabolism and could dramatically enhance bioavailability – even in comparison with nasal sprays and other newer drug delivery systems. The gel stays in the nasal passages and slowly releases its drug formulation while keeping it active for up to seven days. These long-lasting effects, coupled with easy application, offer great attraction as a drug delivery vehicle for patients.
PreveCeutical’s breakthrough Sol-gel technology is currently being tested in connection with various cannabis strains for the development and eventual commercialization of cannabinoid-based Sol-gel products. The company’s Sol-gel research and development program uses five distinct Cannabis sativa L. strains that contain a broad array of CBD:THC concentrations, enabling the development of medical cannabis products designed to treat various ailments and diseases. PreveCeutical’s current focus for the Sol-gel program is on developing Sol-gel formulations that contain fixed CBD:THC concentrations that, when sprayed using a custom applicator, can consistently and safely deliver CBD:THC in predefined ratios to the central nervous system.
Prior to obtaining medicinal cannabis import permits and licenses, which PreveCeutical achieved earlier this year, the company laid the framework for its Sol-gel program by evaluating the non-cannabinoid elements of commercially sourced cannabis plants and assessing the viability of incorporating them into the Sol-gel delivery platform. Through this preliminary screening of non-cannabinoid elements, PreveCeutical gained increased understanding regarding how components (other than CBD and THC) affect the formulation of Sol-gel systems, along with insight into the chemical compatibility, physiochemical stability and biocompatibility of Sol-gels with biological membranes. This has paved the way for optimization of engineered Sol-gels that contain PreveCeutical’s target gelation and adherence properties.
Additionally, the company is in the process of developing a custom Sol-gel applicator. PreveCeutical’s research partner, The University of Queensland, has received multiple Sol-gel spray device prototypes from the company’s manufacturer. Evaluations are ongoing, but the preliminary results have been promising.
For more information, visit the company’s website at www.PreveCeutical.com
More from CannabisNewsWire
CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.
For more information please visit https://www.cbdwire.com